ReviewEuropean respiratory review : an official journal of the European Respiratory Society2010
Mucoactive therapy in COPD.
Review in European respiratory review : an official journal of the European Respiratory Society, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02515799 (A Double-blind, Placebo Controlled, Randomized Crossover Trial to Characterize the Mucolytic Effectiveness of Tacholiquine® in Chronic Bronchitis), which is not on this map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Double-blind, Placebo Controlled, Randomized Crossover Trial to Characterize the Mucolytic Effectiveness of Tacholiquine® in Chronic Bronchitis
Who cites it
15 citing papers in PubMed, 39 citations in OpenAlex.
- Mucolytic Effectiveness of Tyloxapol in Chronic Obstructive Pulmonary Disease - A Double-Blind, Randomized Controlled Trial.PloS one · 2016Trial
- N-acetylcysteine in patients with COPD exacerbations associated with increased sputum.Wiener klinische Wochenschrift · 2015Trial
- Caveolin-1-derived peptide attenuates cigarette smoke-induced airway and alveolar epithelial injury.American journal of physiology. Lung cellular and molecular physiology · 2023Article
- Evaluation of safety and efficacy of inhaled ambroxol in hospitalized adult patients with mucopurulent sputum and expectoration difficulty.Frontiers in medicine · 2023Article
- Clinical Efficacy of Carbocysteine in COPD: Beyond the Mucolytic Action.Pharmaceutics · 2022Review
- Comorbid Conditions in Chronic Obstructive Pulmonary Disease: Potential Therapeutic Targets for Unmet Needs.Journal of clinical medicine · 2020Review
- A Comparison between Two Pathophysiologically Different yet Microbiologically Similar Lung Diseases: Cystic Fibrosis and Chronic Obstructive Pulmonary Disease.International journal of respiratory and pulmonary medicine · 2018Article
- Control of lung defence by mucins and macrophages: ancient defence mechanisms with modern functions.The European respiratory journal · 2016Review
- Review
- Chronic obstructive pulmonary disease (COPD): evaluation from clinical, immunological and bacterial pathogenesis perspectives.Journal of microbiology (Seoul, Korea) · 2014Review
- Chronic obstructive pulmonary disease.Lancet (London, England) · 2012Review
- PPARγ as a Potential Target to Treat Airway Mucus Hypersecretion in Chronic Airway Inflammatory Diseases.PPAR research · 2012Article
- Airway mucus function and dysfunction.The New England journal of medicine · 2010Review
- Mucus hypersecretion in COPD: should we only rely on symptoms?European respiratory review : an official journal of the European Respiratory Society · 2010Article
- Impact of exacerbations on COPD.European respiratory review : an official journal of the European Respiratory Society · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
It has been shown that mucus hypersecretion is associated with greater susceptibility for chronic obstructive pulmonary disease (COPD), excess forced expiratory volume in 1 s decline, hospitalisations and excess mortality. The effects of mucoactive drugs on outcomes have been reviewed in several meta-analyses, the largest one including 26 studies. 21 studies were performed in patients with chronic bronchitis and five in patients with COPD. The majority of these trials were performed with N-acetylcysteine (n = 13) and carbocysteine (n = 3). Overall, there was a significant reduction in exacerbations (0.05 per patient per month) and the number of days with disability (0.56 days per patient per month). Mucolytics were well tolerated and the number of adverse events was lower than with placebo (odds ratio 0.78). In the largest and best designed study with N-acetylcysteine in 523 patients with COPD, the reduction in exacerbations was only observed in patients not taking inhaled corticosteroids. In addition, a 374 mL reduction in functional residual capacity was found. A recent large study (n = 709) with high-dose carbocysteine (1,500 mg·day⁻¹) demonstrated a significant effect on exacerbations (25% reduction) and also reported an improvement in health-related quality of life (-4.06 units in St George's Respiratory Questionnaire). It is unclear what the mechanisms underlying these effects may be and which phenotypes benefit from this treatment. On the basis of this evidence mucoactive drugs may deserve consideration in the long-term treatment of COPD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.